Aachen (ots) -

- The investigational compound has a unique mechanism of action and the 
  potential to become a first-in-class therapy option for the treatment 
  of acute and chronic pain.

- In a Phase I trial, the investigational compound was demonstrated to 
  be safe and well tolerated.

- A Phase II trial will commence later this year.

Grünenthal announced today that the company successfully concluded a Phase I trial evaluating the safety and tolerability of its proprietary NOP agonist. In the trial, which involved 113 healthy participants, the compound was demonstrated to be safe and well tolerated, with no dose-dependent adverse event pattern observed.[1] Grünenthal is now planning to progress its NOP agonist into a Phase II trial that aims to enrol 400 US-based patients undergoing bunionectomy - a well-established model for evaluating the efficacy and safety of a compound as a treatment for acute pain. The trial will commence later this year with results expected in the second half of 2027.

Through its specific selectivity for the nociceptin receptor, Grünenthal's NOP agonist features a unique mechanism of action for the treatment of acute and chronic pain and may present a first-in-class therapy option. The compound has the potential to deliver robust pain relief in a broad range of conditions without the side effects commonly associated with opioids. During the Phase I trial, no such adverse events, including somnolence, constipation or respiratory depression, or events suggesting any abuse liability potential were observed.

"We are excited about the successful completion of our Phase I clinical trial and double down on our efforts to bring the compound to patients", says Uli Brödl, MD, Chief Scientific Officer at Grünenthal. "With selective nociceptin receptor activation, Grünenthal hopes to introduce a new mechanism of action into the pain treatment landscape and provide patients with a much-needed alternative therapy option."

About Bunionectomy

Bunionectomy is the surgical procedure for removing a bunion, an enlargement of bone and soft tissue that develops on the side of the foot, which most commonly occurs in the joint at the base of the big toe: the big toe progressively angles outwards towards the smaller toes, creating a bony bump (hallux valgus deformity). Bunions may be caused by hereditary factors, inflammatory arthritic conditions, or through wearing poorly fitting or pointed shoes that constrict the toes.[2] Bunionectomy is accepted by regulatory authorities as a postoperative hard (bony) tissue pain model in which the analgesic effect of an investigational compound may be evaluated as a treatment for acute pain.[3]

About the NOP Receptor

The Nociceptin/Orphanin Receptor (NOP) is a G protein-coupled receptor whose natural ligand is the 17-amino-acid neuropeptide nociceptin (N/OFQ).[4] NOP agonists have been shown to act as potent analgesics without the potential for abuse liability in pre-clinical models.[5] Although the NOP receptor shares some sequence identity (~60%) with the opioid receptors Mu-OP (MOP), ?-OP (KOP), and ?-OP (DOP), it possesses little or no affinity for opioid peptides or morphine-like compounds. Likewise, opioid receptors possess little affinity towards NOP's endogenous ligand nociceptin.[6]

About Grünenthal

Grünenthal is a global leader in pain management and related diseases. As a science-based, fully integrated pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Our purpose is to change lives for the better - and innovation is our passion. We focus all our activities and efforts on working towards our vision of a World Free of Pain. Grünenthal is headquartered in Aachen, Germany, and has affiliates in 28 countries across Europe, Latin America, and the U.S. Our products are available in approx. 100 countries. In 2025, Grünenthal employed around 4,100 people and achieved revenues of EUR1.8 billion.

More information: www.grunenthal.com and follow us on LinkedIn & Instagram

[1] Grünenthal Data on File

[2] my.clevelandclinic.org (accessed 23 June 2026)

[3] Singla et al. Bunionectomy as an Acute Postoperative Pain Model: Overview of Common Experimental Methods, and Insights from Past Clinical Trials. Journal of Pain Research 2024; 17: 4399-4420.

[4] Henderson G, McKnight AT. The orphan opioid receptor and its endogenous ligand-- nociceptin/orphanin FQ. Trends in Pharmacological Sciences 1997; 18 (8): 293-300.

[5] Lin AP, Ko MC. The therapeutic potential of nociceptin/orphanin FQ receptor agonists as analgesics without abuse liability. ACS Chem Neurosci. 2013; 4(2): 214-24.

[6] Butour et al. Recognition and activation of the opioid receptor-like ORL 1 receptor by nociceptin, nociceptin analogs and opioids. European Journal of Pharmacology 1997; 321(1): 97-103.

Contact:
Christopher Jansen, Global Communications at Grünenthal, christopher.jansen@grunenthal.com

Logo

Tags

More Like This

GRÜNENTHAL'S PROPRIETARY NAV 1.8 INHIBITOR ENTERS CLINICAL DEVELOPMENT

Vertex Announces Positive Results From the VX-548 Phase 3 Program for the Treatment of Moderate-to-Severe Acute Pain

GRÜNENTHAL LICENSES EXCLUSIVE AUSTRALIAN RIGHTS TO QUTENZA® TO CLINECT

Vertex Announces Results from Phase 2 Study of VX-993 for the Treatment of Acute Pain

OKYO Pharma Announces First Patient Dosed in the First Clinical Trial to Treat Neuropathic Corneal Pain

OKYO Pharma to Initiate Neuropathic Corneal Pain Trial for OK-101

OKYO Pharma Announces Start of Phase 2 Clinical Trial to Treat Patients with Neuropathic Corneal Pain

FDA Grants Breakthrough Therapy Designation to VERTANICAL's VER-01, a First-in-Class Non-Opioid Investigational Treatment for Chronic Low Back Pain